- Using conditionally reprogrammed (CR) cells instead of genetically engineered cell lines for in-vitro studies
- Testing or validating indications by leveraging our Functional Diagnosis MiniPDX before in-vivo validation
- Jumping straight to PDX studies after Functional Diagnosis
- Biomarker identification for patient stratification to inform recruitment strategy
Fig. New, optimized R&D roadmap using LIDE Functional Diagnosis platform and conditional reprogramed (CR) cells
Oncology studies done with LIDE also benefit from RWE study in China, where we receive fresh patient samples everyday, many with drug resistance, high profile expression targets or of rare cancer types.